Log In
BCIQ
Print this Print this
 

AG-881

  Manage Alerts
Collapse Summary General Information
Company Agios Pharmaceuticals Inc.
DescriptionInhibitor of mutated isocitrate dehydrogenase 1 (IDH1) and IDH2
Molecular Target Isocitrate dehydrogenase 1 (IDH1) ; Isocitrate dehydrogenase 2 (IDH2)
Mechanism of ActionIsocitrate dehydrogenase 2 (IDH2) inhibitor; Isocitrate dehydrogenase 1 (IDH1) inhibitor
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentPhase I
Standard IndicationSolid tumors
Indication DetailsTreat advanced solid tumors in patients with an IDH1 or IDH2 mutation
Regulatory Designation
PartnerCelgene Corp.

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

$80.0M

$10.0M

$70.0M


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

04/29/2015

$80.0M

$10.0M

$70.0M

Get a free BioCentury trial today